Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41


Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity.

Jones JA, Prior AM, Marreddy RKR, Wahrmund RD, Hurdle JG, Sun D, Hevener KE.

ACS Chem Biol. 2019 Jul 19;14(7):1528-1535. doi: 10.1021/acschembio.9b00293. Epub 2019 Jun 26.


Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains.

Endres BT, Begum K, Sun H, Walk ST, Memariani A, Lancaster C, Gonzales-Luna AJ, Dotson KM, Bassères E, Offiong C, Tupy S, Kuper K, Septimus E, Arafat R, Alam MJ, Zhao Z, Hurdle JG, Savidge TC, Garey KW.

Open Forum Infect Dis. 2019 Feb 9;6(2):ofz013. doi: 10.1093/ofid/ofz013. eCollection 2019 Feb.


Pharmacophore Modeling, Synthesis, and Antibacterial Evaluation of Chalcones and Derivatives.

Zhang M, Prior AM, Maddox MM, Shen WJ, Hevener KE, Bruhn DF, Lee RB, Singh AP, Reinicke J, Simmons CJ, Hurdle JG, Lee RE, Sun D.

ACS Omega. 2018 Dec 31;3(12):18343-18360. doi: 10.1021/acsomega.8b03174. Epub 2018 Dec 26.


The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection.

Marreddy RKR, Wu X, Sapkota M, Prior AM, Jones JA, Sun D, Hevener KE, Hurdle JG.

ACS Infect Dis. 2019 Feb 8;5(2):208-217. doi: 10.1021/acsinfecdis.8b00205. Epub 2018 Dec 13.


New β-lactam - Tetramic acid hybrids show promising antibacterial activities.

Cherian PT, Cheramie MN, Marreddy RKR, Fernando DM, Hurdle JG, Lee RE.

Bioorg Med Chem Lett. 2018 Oct 1;28(18):3105-3112. doi: 10.1016/j.bmcl.2018.07.018. Epub 2018 Jul 17.


Bacterial persister cells tackled.

Hurdle JG, Deshpande A.

Nature. 2018 Apr 5;556(7699):40-41. doi: 10.1038/d41586-018-03440-w. No abstract available.


Solid-Phase Synthesis and Antibacterial Activity of Cyclohexapeptide Wollamide B Analogs.

Tsutsumi LS, Elmore JM, Dang UT, Wallace MJ, Marreddy R, Lee RB, Tan GT, Hurdle JG, Lee RE, Sun D.

ACS Comb Sci. 2018 Mar 12;20(3):172-185. doi: 10.1021/acscombsci.7b00189. Epub 2018 Feb 20.


NF-κB inhibitors, unique γ-pyranol-γ-lactams with sulfide and sulfoxide moieties from Hawaiian plant Lycopodiella cernua derived fungus Paraphaeosphaeria neglecta FT462.

Li CS, Sarotti AM, Huang P, Dang UT, Hurdle JG, Kondratyuk TP, Pezzuto JM, Turkson J, Cao S.

Sci Rep. 2017 Sep 5;7(1):10424. doi: 10.1038/s41598-017-10537-1.


Secondary metabolites from Bacillus amyloliquefaciens isolated from soil can kill Burkholderia pseudomallei.

Boottanun P, Potisap C, Hurdle JG, Sermswan RW.

AMB Express. 2017 Dec;7(1):16. doi: 10.1186/s13568-016-0302-0. Epub 2017 Jan 4.


Frizzled proteins are colonic epithelial receptors for C. difficile toxin B.

Tao L, Zhang J, Meraner P, Tovaglieri A, Wu X, Gerhard R, Zhang X, Stallcup WB, Miao J, He X, Hurdle JG, Breault DT, Brass AL, Dong M.

Nature. 2016 Oct 20;538(7625):350-355. doi: 10.1038/nature19799. Epub 2016 Sep 28.


Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.

Dang UT, Zamora I, Hevener KE, Adhikari S, Wu X, Hurdle JG.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5604-7. doi: 10.1128/AAC.01137-16. Print 2016 Sep.


Design, synthesis and microbiological evaluation of ampicillin-tetramic acid hybrid antibiotics.

Cherian PT, Deshpande A, Cheramie MN, Bruhn DF, Hurdle JG, Lee RE.

J Antibiot (Tokyo). 2017 Jan;70(1):65-72. doi: 10.1038/ja.2016.52. Epub 2016 May 18.


Gastrointestinal localization of metronidazole by a lactobacilli-inspired tetramic acid motif improves treatment outcomes in the hamster model of Clostridium difficile infection.

Cherian PT, Wu X, Yang L, Scarborough JS, Singh AP, Alam ZA, Lee RE, Hurdle JG.

J Antimicrob Chemother. 2015 Nov;70(11):3061-9. doi: 10.1093/jac/dkv231. Epub 2015 Aug 18.


Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile.

Alam MZ, Wu X, Mascio C, Chesnel L, Hurdle JG.

Antimicrob Agents Chemother. 2015 Sep;59(9):5165-70. doi: 10.1128/AAC.01087-15. Epub 2015 Jun 8.


Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.

Feng L, Maddox MM, Alam MZ, Tsutsumi LS, Narula G, Bruhn DF, Wu X, Sandhaus S, Lee RB, Simmons CJ, Tse-Dinh YC, Hurdle JG, Lee RE, Sun D.

J Med Chem. 2014 Oct 23;57(20):8398-420. doi: 10.1021/jm500853v. Epub 2014 Oct 7.


Action of nitroheterocyclic drugs against Clostridium difficile.

Kumar M, Adhikari S, Hurdle JG.

Int J Antimicrob Agents. 2014 Oct;44(4):314-9. doi: 10.1016/j.ijantimicag.2014.05.021. Epub 2014 Jul 25.


Chemical modulation of the biological activity of reutericyclin: a membrane-active antibiotic from Lactobacillus reuteri.

Cherian PT, Wu X, Maddox MM, Singh AP, Lee RE, Hurdle JG.

Sci Rep. 2014 Apr 17;4:4721. doi: 10.1038/srep04721.


The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection.

Wu X, Hurdle JG.

Can J Microbiol. 2014 Apr;60(4):251-4. doi: 10.1139/cjm-2013-0903. Epub 2014 Mar 6.


Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.

Rakesh, Bruhn DF, Scherman MS, Woolhiser LK, Madhura DB, Maddox MM, Singh AP, Lee RB, Hurdle JG, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE.

PLoS One. 2014 Feb 5;9(2):e87909. doi: 10.1371/journal.pone.0087909. eCollection 2014.


Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection.

Wu X, Alam MZ, Feng L, Tsutsumi LS, Sun D, Hurdle JG.

J Appl Microbiol. 2014 Jan;116(1):23-31.


Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux.

Lee RE, Hurdle JG, Liu J, Bruhn DF, Matt T, Scherman MS, Vaddady PK, Zheng Z, Qi J, Akbergenov R, Das S, Madhura DB, Rathi C, Trivedi A, Villellas C, Lee RB, Rakesh, Waidyarachchi SL, Sun D, McNeil MR, Ainsa JA, Boshoff HI, Gonzalez-Juarrero M, Meibohm B, Böttger EC, Lenaerts AJ.

Nat Med. 2014 Feb;20(2):152-158. doi: 10.1038/nm.3458. Epub 2014 Jan 26.


Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Tsutsumi LS, Owusu YB, Hurdle JG, Sun D.

Curr Top Med Chem. 2014;14(1):152-75. Review.


Screening for a diamond in the rough.

Wu X, Hurdle JG.

Chem Biol. 2013 Sep 19;20(9):1091-2. doi: 10.1016/j.chembiol.2013.09.002.


Syntheses and evaluation of macrocyclic engelhardione analogs as antitubercular and antibacterial agents.

Shen L, Maddox MM, Adhikari S, Bruhn DF, Kumar M, Lee RE, Hurdle JG, Lee RE, Sun D.

J Antibiot (Tokyo). 2013 Jun;66(6):319-25. doi: 10.1038/ja.2013.21. Epub 2013 Apr 3.


The membrane as a target for controlling hypervirulent Clostridium difficile infections.

Wu X, Cherian PT, Lee RE, Hurdle JG.

J Antimicrob Chemother. 2013 Apr;68(4):806-15. doi: 10.1093/jac/dks493. Epub 2012 Dec 21.


Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead.

Sun D, Hurdle JG, Lee R, Lee R, Cushman M, Pezzuto JM.

ChemMedChem. 2012 Sep;7(9):1541-5. doi: 10.1002/cmdc.201200253. Epub 2012 Jul 30.


The structure-activity relationship of urea derivatives as anti-tuberculosis agents.

Brown JR, North EJ, Hurdle JG, Morisseau C, Scarborough JS, Sun D, Korduláková J, Scherman MS, Jones V, Grzegorzewicz A, Crew RM, Jackson M, McNeil MR, Lee RE.

Bioorg Med Chem. 2011 Sep 15;19(18):5585-95. doi: 10.1016/j.bmc.2011.07.034. Epub 2011 Jul 24.


Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations.

Hurdle JG, Heathcott AE, Yang L, Yan B, Lee RE.

J Antimicrob Chemother. 2011 Aug;66(8):1773-6. doi: 10.1093/jac/dkr201. Epub 2011 May 31.


Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Hurdle JG, O'Neill AJ, Chopra I, Lee RE.

Nat Rev Microbiol. 2011 Jan;9(1):62-75. doi: 10.1038/nrmicro2474. Review.


Structural studies of pterin-based inhibitors of dihydropteroate synthase.

Hevener KE, Yun MK, Qi J, Kerr ID, Babaoglu K, Hurdle JG, Balakrishna K, White SW, Lee RE.

J Med Chem. 2010 Jan 14;53(1):166-77. doi: 10.1021/jm900861d.


A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.

Budha NR, Lee RB, Hurdle JG, Lee RE, Meibohm B.

Tuberculosis (Edinb). 2009 Sep;89(5):378-85. doi: 10.1016/ Epub 2009 Sep 11.


Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections.

Hurdle JG, Yendapally R, Sun D, Lee RE.

Antimicrob Agents Chemother. 2009 Sep;53(9):4028-31. doi: 10.1128/AAC.00457-09. Epub 2009 Jul 6.


Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity.

Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE.

Bioorg Med Chem. 2009 May 15;17(10):3588-94. doi: 10.1016/j.bmc.2009.04.005. Epub 2009 Apr 9.


Novel acyl phosphate mimics that target PlsY, an essential acyltransferase in gram-positive bacteria.

Grimes KD, Lu YJ, Zhang YM, Luna VA, Hurdle JG, Carson EI, Qi J, Kudrimoti S, Rock CO, Lee RE.

ChemMedChem. 2008 Dec;3(12):1936-45. doi: 10.1002/cmdc.200800218.


A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.

Hurdle JG, Lee RB, Budha NR, Carson EI, Qi J, Scherman MS, Cho SH, McNeil MR, Lenaerts AJ, Franzblau SG, Meibohm B, Lee RE.

J Antimicrob Chemother. 2008 Nov;62(5):1037-45. doi: 10.1093/jac/dkn307. Epub 2008 Aug 7.


N-substituted 3-acetyltetramic acid derivatives as antibacterial agents.

Yendapally R, Hurdle JG, Carson EI, Lee RB, Lee RE.

J Med Chem. 2008 Mar 13;51(5):1487-91. doi: 10.1021/jm701356q. Epub 2008 Feb 19.


Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents.

Hurdle JG, O'Neill AJ, Chopra I.

Antimicrob Agents Chemother. 2005 Dec;49(12):4821-33. Review. No abstract available.


Analysis of mupirocin resistance and fitness in Staphylococcus aureus by molecular genetic and structural modeling techniques.

Hurdle JG, O'Neill AJ, Ingham E, Fishwick C, Chopra I.

Antimicrob Agents Chemother. 2004 Nov;48(11):4366-76.


Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections.

Hurdle JG, O'Neill AJ, Chopra I.

J Antimicrob Chemother. 2004 Aug;54(2):549-52. Epub 2004 Jul 8.


Supplemental Content

Loading ...
Support Center